2025-04-08 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0. Key Figures Summary:**

RXRX's current price is significantly below its moving averages, indicating a downtrend.  Negative EPS and highly volatile profitability metrics raise serious concerns.  The stock has significantly underperformed the S&P 500.


**1. Performance Comparison with S&P 500 (VOO):**

Recursion Pharmaceuticals Inc. (RXRX) is a clinical-stage biopharmaceutical company discovering and developing novel small molecule drugs.

* **RXRX Cumulative Return:** -56.92%
* **VOO (S&P 500) Cumulative Return:** -5.50%
* **Return Difference:** -51.4% (RXRX underperformed VOO by 51.4 percentage points).
* **Relative Underperformance:** 25.8% (This means RXRX's underperformance relative to VOO is in the 25.8th percentile of its historical underperformance range).

**Alpha and Beta Analysis:**  The provided data shows consistently negative alpha values, indicating underperformance compared to the market benchmark, and high beta values, implying significant volatility and sensitivity to market movements.  The beta has decreased over time which is a positive sign. However, the extremely negative alpha and high beta highlight the risky nature of RXRX.

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|--------|--------|
| 2021-2023  | -11.0%  | 57.1%  | -14.0% | 4.0    |        |
| 2022-2024  | 0.0%   | 57.1%  | -20.0% | 2.7    |        |
| 2023-2025  | -15.0%  | 56.8%  | -29.0% | 1.7    |        |


**2. Recent Price Movement:**

* **Closing Price:** $4.20
* **5-Day Moving Average:** $4.73
* **20-Day Moving Average:** $5.88
* **60-Day Moving Average:** $7.06

The price is significantly below all three moving averages, strongly suggesting a bearish trend. The recent price change of -0.94% reflects a minor decline.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4792 (High Risk) - This indicates a high level of risk associated with the stock.
* **RSI:** 19.41 (Oversold) –  Suggests the stock is oversold, potentially indicating a bounce, but not necessarily a sustainable recovery.
* **PPO:** -3.26 (Bearish) – A negative PPO further confirms the bearish trend.
* **Relative Strength Change (20-day):** +15.1% (Short-term upward movement) - This indicates a recent short-term upward price movement, which is at odds with longer-term trends.
* **Expected Return:** -68.3% – This indicates a very pessimistic outlook for long-term returns relative to the S&P 500.  This extreme negative expected return highlights the substantial risk associated with this investment.


**4. Recent Earnings Analysis:**

RXRX has consistently reported negative EPS and low revenue. There is no clear trend of improvement.


| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-06 | -0.34  | $0.03B      |
| 2024-08-08 | -0.4   | $0.01B      |
| 2024-05-09 | -0.39  | $0.01B      |
| 2023-11-09 | -0.43  | $0.01B      |
| 2024-11-06 | -0.43  | $0.01B      | *(Duplicate entry?)*


**5. Financial Information:**

The financial data reveals significant challenges:

* **Revenue and Profitability:** Revenue is very low, and profit margins are extremely erratic, swinging wildly between substantial losses and modest gains. The negative profit margin in the last quarter is particularly alarming.

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%       |
| 2024-06-30 | $0.01B    | 36.14%       |
| 2024-03-31 | $0.01B    | 17.23%       |
| 2023-12-31 | $0.01B    | 6.99%        |


* **Capital and Profitability:** Equity is fluctuating, and ROE is consistently negative, showing that the company is not generating returns on its invested capital.

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2024-12-31 | $1.03B   | -17.29%  |
| 2024-09-30 | $0.52B   | -18.27%  |
| 2024-06-30 | $0.58B   | -16.69%  |
| 2024-03-31 | $0.40B   | -22.78%  |
| 2023-12-31 | $0.46B   | -20.07%  |


**6. Overall Analysis:**

RXRX presents a highly risky investment.  The stock is significantly underperforming the market, showing consistently negative alpha and high beta.  Financial statements reveal low revenue, highly erratic profitability, and consistently negative ROE.  Technical indicators point towards a bearish trend, though the recent short-term upward movement might suggest a temporary bounce.  The extremely negative expected return (-68.3%) reinforces the high risk associated with this stock.  Considering the current financial situation and market performance, a strong caution is advised before investing in RXRX.  Further research into the company’s long-term strategic plans and pipeline is crucial before making any investment decisions.  The extremely negative expected return warrants further scrutiny.  Unless there's a substantial change in the company's fundamentals or a significantly altered market outlook, investment should be approached with extreme caution.
